about
Biomarkers in phase I-II chemoprevention trials: lessons from the NCI experienceAltered cJUN expression: an early event in human lung carcinogenesisLung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated researchRegulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinicCharacterization and management of cardiac involvement of thymic epithelial tumorsA phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakiaA phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.Hepatoid adenocarcinoma of the lung metastasizing to the tonsil.Pioglitazone-mediated reversal of elevated glucose metabolism in the airway epithelium of mouse lung adenocarcinomas.Intermediate Markers and Molecular Genetics of Lung Carcinogenesis.PPARĪ³ in head and neck cancer preventionCognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research.Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.Phase II cancer prevention clinical trialsMetformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Cancer and inflammation: promise for biologic therapy.Short- and long-term lung cancer risk associated with noncalcified nodules observed on low-dose CTFifty years of tobacco carcinogenesis research: from mechanisms to early detection and prevention of lung cancerA phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectumMolecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trialChemoprevention of lung cancer: new directions.Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.Long-term effects of inhaled budesonide on screening-detected lung nodules.Use of markers for the detection and treatment of lung cancerHow should we move the field of chemopreventive agent development forward in a productive manner?Validation of LOH profiles for assessing oral cancer risk.A web-based screening and accrual strategy for a cancer prevention clinical trial in healthy smokersRandomized phase II trial of sulindac for lung cancer chemoprevention.Repurposing old drugs to chemoprevention: the case of metformin.18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumorsSelumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.The Ninth Annual American Association of cancer research international conference on frontiers in cancer prevention research.Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesTransforming Cancer Prevention through Precision Medicine and Immune-oncology.Primer: first do no harm--when is it appropriate to plan a cancer prevention clinical trial?A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.AACR Cancer Progress Report 2015Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.Randomized controlled trials of the efficacy of lung cancer screening by sputum cytology revisited: a combined mortality analysis from the Johns Hopkins Lung Project and the Memorial Sloan-Kettering Lung Study.
P50
Q26774585-D38FF5CA-40D7-400F-BF0E-73B735CB6CE8Q28272085-3A02A670-EA78-455A-9A4B-DC49BC753D57Q28754732-1F9AEA14-C3C7-4CAD-B5B0-F10D83522D6BQ30498812-6FA28E95-68F6-43A8-9451-DA02CCF9475DQ30532773-E6B4E78A-9CDF-4C6A-A30D-D51BC9FCEA00Q31123048-28B929F5-3CBD-4546-B946-5B1B70F3F657Q33161027-CD56DD63-DFA7-49FF-A448-3707DD4FA61BQ33417499-BADF4670-EE11-40F8-B829-C7CF01EB6032Q33686475-4EAEE462-3E0A-4C19-8E1B-1417614A83EFQ33877772-884E34B7-3991-406A-A215-7A59AFA1C405Q33890620-CD41212E-A46D-41D0-AE17-CA9FA07AA49EQ33896090-53A02383-79B2-4C85-B720-D3909385C41CQ33924771-F760E440-189F-4CB5-B947-742751902E0AQ33931069-82767D49-50CD-41FA-8A56-6F398E2A334CQ34112511-2F428E39-103B-4608-B606-C1671C175221Q34135248-FD46D67C-D767-4D27-BC9C-9D0732ACE84EQ34139732-B853D412-BE10-4E4E-BCD1-DECD1E376B73Q34389438-0A3E4A8B-9D64-427D-9C61-72BAA522644BQ34976530-7232E2EC-A0B2-4756-AE93-10A0003EC7A7Q35163569-7ADE080C-3B43-43F6-8C44-66667FEC3CBCQ35168763-DCC2C901-F26A-447C-971D-39652B947EA7Q35194277-FCA8ADBF-ACD5-4BE7-9E3A-28C0F2F2BF95Q35462240-E78A8D52-B523-4884-8115-C930673B40D0Q35511821-055F0202-A41C-4C3C-93CE-A9312136DBCEQ35867890-91F9032A-4910-4F3D-B9A7-6A4F581C73B4Q36008186-E6B98DA9-2918-4453-A707-A9EB73406009Q36213589-3AE9F173-EB3B-4617-BBE4-7C265B9C2BA2Q36286457-6581955C-96C8-4E23-B702-73936F051D98Q36592529-1CC732B9-D4B0-4727-81FD-657A97CD4261Q36679911-F44FABC3-AD4C-4F7C-A12B-87D536762DBDQ36698218-51E35503-3BBA-4A00-BD79-E97DFE0BD3B8Q36716682-1E504928-29BA-4CDC-96F1-85411E273528Q36786526-3EEB5F91-9677-4DD1-ABA5-D0059FCD9ACAQ37111529-DF8D3A58-74EF-46DA-A092-0ADF2D6E104FQ37114360-D85C58E1-C213-4562-9530-29BCBBF3145BQ37150734-3CCC1B09-AAB3-4BC4-A17E-B1DE8AF0C2B4Q37200511-CB01FBC0-BBD1-4C0A-AB71-5FFEA4A9DF58Q37210896-0E003286-B895-4387-A5F3-26935C926775Q37212135-709DD955-6E57-4972-B764-48E89FF7FF12Q37399735-6AB57352-6E80-43D8-9DFF-B1684803FA32
P50
description
cancer researcher
@en
name
Eva Szabo
@en
Szabo E
@ast
Szabo E
@nl
type
label
Eva Szabo
@en
Szabo E
@ast
Szabo E
@nl
altLabel
Szabo E
@en
prefLabel
Eva Szabo
@en
Szabo E
@ast
Szabo E
@nl
P106
P31
P496
0000-0003-3891-0942